EUCTR2009-011786-80-IT进行中（未招募）不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus Infection - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females between the ages of 18 and 70 years, inclusive, at the time of signing informed consent. 2. No prior therapy for chronic HCV, other than up to 2 weeks of single-agent therapy with a direct-acting antiviral agent, including but not limited to, a protease or polymerase inhibitor. 3. Genotype 1, 2, 3, or 4 HCV RNA. [...]
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Mixed genotype HCV infection. 2. Current or prior history of decompensated liver disease, including any of the following: current or prior history of encephalopathy of any grade, current or prior history of variceal bleeding, current or prior history of ascites, total serum bilirubin >1.5 mg/dL (unless due to Gilbert s disease), albumin <3.5 g/dL, or INR >1.2 3. Currently lactating or breast-feeding . [?]
研究者
相似试验
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioEUCTR2009-011786-80-CZZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioChronic Hepatitis C Virus InfectionMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-011786-80-ATZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29Administered in Combination with Ribavirin to Treatment-Naive Subjects with ChronicHepatitis C Virus InfectioChronic Hepatitis C Virus InfectionMedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-011786-80-BEZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioEUCTR2009-011786-80-DEZymoGenetics, Inc.600
进行中（未招募）
1 期
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29Administered in Combination with Ribavirin to Treatment-Naive Subjects with ChronicHepatitis C Virus InfectioChronic Hepatitis C Virus InfectionMedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-011786-80-FRZymoGenetics, Inc.600